Clinical characteristics of unregulated psychoactive supplement exposures: a 15-year multicenter study of kratom, phenibut, and tianeptine

Introduction Unregulated psychoactive “supplements” including kratom, phenibut, and tianeptine are readily accessible, raising concern for toxicity and dependence owing to their GABA and opioid receptor activity; however, clinical features associated with their use are poorly characterized. We describe hospital presentations and management of kratom, phenibut, and tianeptine exposures.Methods We analyzed data from the Toxicology Investigators Consortium (ToxIC) Core Registry, which prospectively collects information on patients managed by medical toxicologists (1 January 2010–31 December 2024). All cases involving kratom, phenibut, and/or tianeptine exposures were included. Demographics, exposure circumstances, clinical presentation, management, and outcomes were examined.Results We identified 152 patient encounters involving kratom (n = 97), phenibut (n = 44) and/or tianeptine (n = 11), with case counts increasing over time. Median age was 35 years (IQR 26–42 years), and 127 (83.6%) were male. Co-ingestions were common (n = 73; 48.0%) frequently involving other psychoactive supplements (n = 27; 17.8%), stimulants (n = 23; 15.1%) and/or opioids (n = 22; 14.5%). Most consultations involved intentional use (n = 131; 86.2%), including euphoria (n = 60; 39.5%), perceived therapeutic/wellness benefit (n = 18; 11.8%) and withdrawal self-management (n = 13; 8.6%). Thirty-five encounters (23.0%) resulted in intensive care admission and one patient died. Addiction treatment infrequently involved buprenorphine/naloxone (n = 15; 9.9%). At hospital discharge 16 (10.5%) patients received naloxone overdose prevention kit education and/or prescription.Discussion Psychoactive supplement exposures evaluated by medical toxicologists were associated with substantial morbidity, with nearly one-quarter requiring intensive care unit admission. Withdrawal was common, and nearly half of encounters involved co-ingestants.Conclusion Hospital presentations involving kratom, phenibut, and tianeptine increased over time, supporting recognition of these substances as emerging drugs of misuse rather than benign supplements. These findings highlight opportunities to strengthen addiction-focused care, regulatory oversight and public education.

Authors

Institutions

Publication Details

Journal
Clinical Toxicology
Published
2026-11-20
DOI
https://doi.org/10.1080/15563650.2026.2761523
Primary Topic
Poisoning and overdose treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Clinical characteristics of unregulated psychoactive supplement exposures: a 15-year multicenter study of kratom, phenibut, and tianeptine

Jessica T. Kent, Matthew Hacker Teper, Yaron Finkelstein, On behalf of the Toxicology Investigators Consortium et al.
2 links
Clinical Toxicology
Poisoning and overdose treatments
article

Clinical characteristics of unregulated psychoactive supplement exposures: a 15-year multicenter study of kratom, phenibut, and tianeptine

Jessica T. Kent, Matthew Hacker Teper, Yaron Finkelstein, On behalf of the Toxicology Investigators Consortium, Rachel Culbreth
article en

Abstract

Introduction Unregulated psychoactive “supplements” including kratom, phenibut, and tianeptine are readily accessible, raising concern for toxicity and dependence owing to their GABA and opioid receptor activity; however, clinical features associated with their use are poorly characterized. We describe hospital presentations and management of kratom, phenibut, and tianeptine exposures.Methods We analyzed data from the Toxicology Investigators Consortium (ToxIC) Core Registry, which prospectively collects information on patients managed by medical toxicologists (1 January 2010–31 December 2024). All cases involving kratom, phenibut, and/or tianeptine exposures were included. Demographics, exposure circumstances, clinical presentation, management, and outcomes were examined.Results We identified 152 patient encounters involving kratom (n = 97), phenibut (n = 44) and/or tianeptine (n = 11), with case counts increasing over time. Median age was 35 years (IQR 26–42 years), and 127 (83.6%) were male. Co-ingestions were common (n = 73; 48.0%) frequently involving other psychoactive supplements (n = 27; 17.8%), stimulants (n = 23; 15.1%) and/or opioids (n = 22; 14.5%). Most consultations involved intentional use (n = 131; 86.2%), including euphoria (n = 60; 39.5%), perceived therapeutic/wellness benefit (n = 18; 11.8%) and withdrawal self-management (n = 13; 8.6%). Thirty-five encounters (23.0%) resulted in intensive care admission and one patient died. Addiction treatment infrequently involved buprenorphine/naloxone (n = 15; 9.9%). At hospital discharge 16 (10.5%) patients received naloxone overdose prevention kit education and/or prescription.Discussion Psychoactive supplement exposures evaluated by medical toxicologists were associated with substantial morbidity, with nearly one-quarter requiring intensive care unit admission. Withdrawal was common, and nearly half of encounters involved co-ingestants.Conclusion Hospital presentations involving kratom, phenibut, and tianeptine increased over time, supporting recognition of these substances as emerging drugs of misuse rather than benign supplements. These findings highlight opportunities to strengthen addiction-focused care, regulatory oversight and public education.

Clinical Toxicology
St. Michael's Hospital (CA), University of Toronto (CA), The Hospital for Sick Children (CA), American College of Medical Toxicology (US)
Good health and well-being
Poisoning and overdose treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon